NPF
BLUE

Norris Perne & French’s bluebird bio BLUE Stock Holding History

Norris Perne & French’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$5.2K – 144
2024
Q3 		$5.2K Hold
500
– – ﹤0.01% 146
2024
Q2 		$9.84K Hold
500
– – ﹤0.01% 144
2024
Q1 		$12.8K Hold
500
– – ﹤0.01% 146
2023
Q4 		$13.8K Buy
+500
New +$30.5K ﹤0.01% 136

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Norris Perne & French's BLUE Position: Q4 2024 in Review

Norris Perne & French sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 500 shares — an estimated $5.2K sold.

Norris Perne & French first reported a position in BLUE in Q4 2023 and held it in 4 quarters. The position peaked at $13.8K in Q4 2023. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • Norris Perne & French reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • Norris Perne & French sold 500 bluebird bio shares in Q4 2024, an estimated $5.2K.
  • Norris Perne & French first reported a position in bluebird bio in Q4 2023 and held it in 4 quarters.
  • Norris Perne & French's bluebird bio position peaked at $13.8K in Q4 2023.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on Norris Perne & French's 13F filing for Q4 2024, filed 23 Jan 2025.